- Home
- URGN vs ELDN Comparison
URGN vs ELDN Comparison
Compare URGN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ELDN
- Stock Information
- Founded
- URGN 2004
- ELDN 2004
- Country
- URGN United States
- ELDN United States
- Employees
- URGN N/A
- ELDN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- ELDN Health Care
- Exchange
- URGN Nasdaq
- ELDN Nasdaq
- Market Cap
- URGN 831.6M
- ELDN 178.4M
- IPO Year
- URGN 2017
- ELDN N/A
- Fundamental
- Price
- URGN $18.90
- ELDN $3.03
- Analyst Decision
- URGN Strong Buy
- ELDN Strong Buy
- Analyst Count
- URGN 8
- ELDN 2
- Target Price
- URGN $29.00
- ELDN $12.50
- AVG Volume (30 Days)
- URGN 1.3M
- ELDN 619.6K
- Earning Date
- URGN 08-07-2025
- ELDN 08-18-2025
- Dividend Yield
- URGN N/A
- ELDN N/A
- EPS Growth
- URGN N/A
- ELDN N/A
- EPS
- URGN N/A
- ELDN N/A
- Revenue
- URGN $91,871,000.00
- ELDN N/A
- Revenue This Year
- URGN $39.80
- ELDN N/A
- Revenue Next Year
- URGN $108.94
- ELDN N/A
- P/E Ratio
- URGN N/A
- ELDN N/A
- Revenue Growth
- URGN 8.98
- ELDN N/A
- 52 Week Low
- URGN $3.42
- ELDN $2.38
- 52 Week High
- URGN $19.36
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- URGN 75.30
- ELDN 38.45
- Support Level
- URGN $17.68
- ELDN $3.63
- Resistance Level
- URGN $19.36
- ELDN $3.95
- Average True Range (ATR)
- URGN 1.05
- ELDN 0.28
- MACD
- URGN 0.27
- ELDN -0.07
- Stochastic Oscillator
- URGN 92.16
- ELDN 10.97
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.